Loading the player...
Information
Exploring Psilocybin-Assisted Emerging Therapeutic Applications, Benefits, & Risks
Length: 57 Minutes
This program will expire and must be completed by 08/29/28.
** Please note this program was a part of the VOCCME 2025. You will not want to choose this program if you completed this individual program as part of the VOCCME 2025. **
This presentation will explore the promising role of psilocybin in treating mental health concerns, such as depression, anxiety, PTSD, and addiction. The pros and cons for using psilocybin will be reviewed by the presenter. They will also discuss the neurobiological mechanisms by which psilocybin acts on serotonin receptors in the brain, potentially leading to profound alterations in mood and cognition. The presentation will review recent clinical trials and research demonstrating the efficacy and safety of psilocybin as a therapeutic intervention, alongside considerations for appropriate patient selection, dosing protocols, and the importance of a supportive therapeutic environment. Additionally, we will address the legal and ethical implications of psilocybin use in clinical practice, while also dispelling common myths surrounding psychedelics.
Learning Objectives:
• Learners will gain knowledge about the legal status of psilocybin in their regions, including regulatory frameworks and the ethical considerations surrounding its use, such as informed consent and patient autonomy.
• Learners will critically evaluate recent clinical studies and research findings that support the use of psilocybin in treating mental health disorders such as depression, anxiety, PTSD, and addiction, recognizing the strengths and limitations of this body of evidence.
• Learners will outline effective strategies for monitoring patient outcomes during and after psilocybin therapy, including recognizing adverse effects and assessing the long-term benefits of treatment.
• Learners will develop the skills necessary to determine patient eligibility for psilocybin treatment, understanding which conditions may benefit and identifying any contraindications or risk factors that must be considered.
Accreditation Statements:
This program is co-sponsored by the Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) and the Osteopathic Physicians and Surgeons of Oregon (OPSO). Both osteopathic associations are accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.
The program has been designated for a maximum of one (1) AOA Category 1-A Credit(s) by the co-sponsors who have authorized the Missouri Association of Osteopathic Physicians and Surgeons to report CME and specialty credits to the AOA commensurate with the extent of the physician's participation in this activity.
The Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) designates this conference for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Disclosure:
The Virtual CME Committee, consisting of representatives from the Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) and the Osteopathic Physicians and Surgeons of Oregon (OPSO), has no relevant financial relationships with any organization producing, marketing, reselling, distributing health care goods or services consumed by, or used on, patients relative to the content of these presentations.
Grievance Policy:
All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to the MAOPS Executive Director, who will then forward said grievance to the Virtual CME Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, they can then submit a complaint in writing to the Council on Continuing Medical Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
Dan Golletz, PhD
Dr. Daniel Golletz graduated with a Bachelor of Arts in Economics from the University of Illinois at Urbana-Champaign in 1986. He then completed his Bachelor of Arts in Psychology at the University of Illinois at Chicago in 1989. He completed his Masters and Ph.D. in Clinical Psychology from the University of Washington in Seattle, Washington. He has been a Licensed Psychologist in Oregon since 1998. His specialties include treatment of Anxiety, Depression, PTSD, Chronic Pain, and Adult ADHD. His latest passions include psychedelic science and pain science.
Dr. Golletz has been the co-owner with his wife, Kim, of Peak Psychological Services, P.C., in Corvallis, Oregon, since 1994. They proudly celebrated their 30th year in service to Corvallis and the mid-Willamette Valley. Additionally, they have been closely following the "psychedelic renaissance" for the past 6 years and believe that psychedelic-assisted therapies have the potential to improve the efficacy of psychotherapy and to address some of the most challenging issues in mental health today. They were both active in the campaign to make Oregon the first state in the nation to provide a regulated and legal program for providing psilocybin services to the public. Dr. Golletz has completed advanced training in psychedelic-assisted therapy and has spoken to professional and lay audiences in Oregon on the topic. Dr. Golletz and his wife, Kim, are preparing to open a state-licensed Psilocybin Service Center ("Soluna Center") in Corvallis by early 2025.
Dr. Dan Golletz discloses he has no relevant financial relationships with any organization producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients relative to the content of this presentation.
Kim Golletz, PhD
Dr. Kimberley Golletz graduated with a Bachelors in Psychology from the University of Cincinnati in 1983. She then completed her Master's degree in Clinical Psychology in 1985 and her Doctor of Philosophy at Vanderbilt University in Nashville, Tennessee, in 1987. She has been a Licensed Psychologist in Oregon since 1994. Her career has combined clinical work and teaching. Her areas of specialty are psychological assessment and psychotherapy for children and families.
Dr. Golletz has been the co-owner with her husband, Dan, of Peak Psychological Services, P.C., in Corvallis, Oregon, since 1994. They proudly celebrated their 30th year in service to Corvallis and the mid-Willamette Valley. Additionally, they have been closely following the "psychedelic renaissance" for the past 6 years and believe that psychedelic-assisted therapies have the potential to improve the efficacy of psychotherapy and to address some of the most challenging issues in mental health today. They were both active in the campaign to make Oregon the first state in the nation to provide a regulated and legal program for providing psilocybin services to the public. Dr. Golletz has completed advanced training in psychedelic-assisted therapy and has spoken to professional and lay audiences in Oregon on the topic. Dr. Golletz and her husband, Dan, are preparing to open a state-licensed Psilocybin Service Center ("Soluna Center") in Corvallis by early 2025.
Dr. Kim Golletz discloses she has no relevant financial relationships with any organization producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients relative to the content of this presentation.
